We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 393

Federal Circuit invalidates Myriad primer and method claims as lacking subject matter eligibility

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • December 17 2014

In a case styled as In re BRCA1- and BRCA2-Based Hereditary Cancer Test Patent Litigation (also known as Myriad v. Ambry), the Federal Circuit held

Sequenom deal may avoid Federal Circuit decision

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • December 15 2014

Less than a month after their case was argued at the Federal Circuit, Illumina Inc. and Sequenom Inc. have announced a deal to settle their patent

Federal Circuit says secret prior art is prior art for all purposes

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • December 11 2014

In Tyco Healthcare Group LP v. Ethicon Endo-Surgery, Inc., the Federal Circuit agreed with the district court that Ethicon's prototype constituted

Another patent challenge for personalized medicine

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • December 8 2014

The U.S. Supreme Court's recent trilogy of patent-eligibility decisions (Prometheus, Myriadand Alice) have called into question the validity of many

Federal Circuit notes high burden of invoking inherency for obviousness

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • December 5 2014

In Par Pharmaceutical Inc. v. Twi Pharmaceuticals, Inc., the Federal Circuit vacated and remanded the district court decision holding the Par claims

Defense to patent infringement if acts were performed in a “quasigovernmental” capacity pursuant to a legal obligation

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • December 2 2014

A recent Federal Circuit opinion highlights a defense that is available to defendants whose alleged infringement occurred through activities that

Third time is the charm for WildTangent challenge of patent eligibility of Ultramercial patent

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • November 17 2014

In its third opinion reviewing the same district court decision, the Federal Circuit this time affirmed the district court's grant of WildTangent's

Federal Circuit’s post-Alice eligibility analysis of business methods

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • November 16 2014

The Federal Circuit in Ultramercial, Inc. v. WildTangent, Inc., held that an "entrepreneurial" multi-step process for distributing copyrighted media

Federal Circuit looks for inventive concept in Sequenom patent

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • November 10 2014

On November 7, 2014, the Federal Circuit heard oral arguments in Aria Diagnostics, Inc. v. Sequenom, Inc., where Sequenom is appealing the district

District court finds Genetic Technologies patent invalid under 101 on motion to dismiss

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • November 6 2014

Judge Stark of the U.S. District Court for the District of Delaware granted defendants' motion to dismiss Genetic Technologies, Ltd.'s patent